Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model

Blood Cancer Journal

Volumn 4, Issue 6, 2014, Pages

  Schwarzer, R ^a,b   Nickel, N ^a   Godau, J ^a   Willie, B M ^a   Duda, G N ^a   Cirovic, B ^c   Leutz, A ^c   Manz, R ^d   Bogen, B ^e,f   Dorken B ^a,c   Jundt, F ^a,g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d University of Lu Beck   (Germany)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; GSI XII; IMMUNOGLOBULIN A; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG; BENZYLOXYCARBONYL-ISOLEUCYL-LEUCINAL; DIPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE ATROPHY; BONE DISEASE; CELL DIFFERENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; TRABECULAR BONE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BONE DISEASES; DISEASE FREE SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BONE DISEASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DIPEPTIDES; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; RANDOM ALLOCATION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903744269     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.37     Document Type: Article

References (36)

1. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN). Blood 2011; 118: 4519-4529.
2. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398-3403.
3. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511-3515.
4. Jundt F, Acikgoz O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008; 22: 1587-1594.
5. Schwarzer R, Kaiser M, Acikgoez O, Heider U, Mathas S, Preissner R et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia 2008; 22: 2273-2277.
6. Schwarzer R, Dorken B, Jundt F. Notch is an essential upstream regulator of NF-kappa B and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012; 26: 806-813.
7. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-233.
8. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 2012; 13: 654-666.
9. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32: 14-27.
10. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776.
11. Colombo M, Mirandola L, Platonova N, Apicella L, Basile A, Figueroa AJ et al. Notch-directed microenvironment reprogramming in myeloma: A single path to multiple outcomes. Leukemia 2013; 27: 1009-1018.
12. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004; 104: 3697-3704.
13. Takeuchi T, Adachi Y, Ohtsuki Y. Skeletrophin, a novel ubiquitin ligase to the intracellular region of Jagged-2, is aberrantly expressed in multiple myeloma. Am J Pathol 2005; 166: 1817-1826.
14. Ghoshal P, Nganga AJ, Moran-Giuati J, Szafranek A, Johnson TR, Bigelow AJ et al. Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res 2009; 69: 4380-4387.
15. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004; 103: 3503-3510.
16. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008; 111: 2220-2229.
17. Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K et al. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun 2012; 428: 518-524.
18. Chiron D, Maiga S, Descamps G, Moreau P, Le Gouill S, Marionneau S et al. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis 2012; 48: 247-253.
19. Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B et al. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138 MM-cell proliferation. Leukemia 2012; 26: 1402-1405.
20. Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr) 2011; 34: 545-551.
21. Mirandola L, Apicella L, Colombo M, Yu Y, Berta DG, Platonova N et al. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 2013; 27: 1558-1566.
22. Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One 2012; 7: E51892.
23. Lauritzsen GF, Bogen B. The role of idiotype-specific, CD4 T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 1993; 148: 177-188.
24. Collin-Osdoby P, Osdoby P. RANKL-mediated osteoclast formation from murine RAW 264.7 cells. Methods Mol Biol 2012; 816: 187-202.
25. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O et al. Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006; 7: R100.
26. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010; 25: 1468-1486.
27. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005; 333: 200-205.
28. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901.
29. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002; 277: 41147-41156.
30. Yamada T, Yamazaki H, Yamane T, Yoshino M, Okuyama H, Tsuneto M et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. Blood 2003; 101: 2227-2234.
31. Choi YH, Ann EJ, Yoon JH, Mo JS, Kim MY, Park HS. Calcium/ calmodulindependent protein kinase IV (CaMKIV) enhances osteoclast differentiation via the up-regulation of Notch1 protein stability. Biochim Biophys Acta 2013; 1833: 69-79.
32. Fukushima H, Nakao A, Okamoto F, Shin M, Kajiya H, Sakano S et al. The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol 2008; 28: 6402-6412.
33. Duan L, de Vos P, Fan M, Ren Y. Notch is activated in RANKL-induced osteoclast differentiation and resorption. Front Biosci 2008; 13: 7064-7071.
34. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005; 202: 1261-1269.
35. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19: 192-205.
36. Riedel SS, Mottok A, Brede C, Bauerlein CA, Jordan Garrote AL, Ritz M et al. Noninvasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS One 2012; 7: E52398.